Andrew D. Dickinson, serving as the Chief Financial Officer for Gilead Sciences, Inc. (NASDAQ:GILD), has finalized a transaction involving the sale of company equity. According to a Form 4 filing submitted to the Securities and Exchange Commission, Dickinson disposed of 3,000 shares of Gilead Sciences common stock on June 15, 2026.
The transaction was executed at a price of $125.40 per share, resulting in a total sale value of $376,200. The disposition was carried out pursuant to a Rule 10b5-1 trading plan, a mechanism designed to facilitate insider trading in compliance with securities regulations. Dickinson originally adopted this specific trading plan on August 29, 2024. Post-transaction, Dickinson's direct holdings in Gilead Sciences common stock stand at 171,646 shares.
Market metrics indicate that Gilead Sciences is currently trading at a price-to-earnings ratio of 17.25. Data from InvestingPro suggests this valuation is low when compared to near-term earnings growth projections. The biotechnology firm maintains a market capitalization of $157.85 billion and provides shareholders with a dividend yield of 2.58%. Furthermore, InvestingPro's Fair Value analysis indicates that the stock may be undervalued at its current trading levels. Subscribers to InvestingPro have access to additional exclusive tips for GILD, alongside comprehensive Pro Research Reports covering over 1,400 top US stocks.
In regulatory developments, Gilead Sciences announced that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for Yeztugo. Yeztugo is a once-weekly oral pill designed for HIV prevention. The FDA has established a target action date of February 2, 2027, for this application. The drug's development is supported by clinical trials designated as PURPOSE 1 and PURPOSE 2.
Market analysts at Cantor Fitzgerald have reiterated an Overweight rating on Gilead Sciences. The firm maintains a price target of $155.00 for the stock, citing these recent regulatory developments as supportive factors. Additionally, Gilead Sciences and Merck have reported positive outcomes from the phase 3 ISLEND-1 and ISLEND-2 trials, which evaluate a once-weekly HIV treatment. Conversely, the companies announced negative results from the EVOKE-03 study. This study examined the combination of Trodelvy and Keytruda in lung cancer patients.
Gilead Sciences is also engaged in significant humanitarian efforts. The company donated over 2,000 vials of remdesivir to Uganda to support the response to an Ebola outbreak. Gilead is preparing additional supplies and collaborating with partners including the Democratic Republic of the Congo and the World Health Organization. These actions underscore the company's focus on global health initiatives alongside its HIV treatment advancements.